Do you offer ADT in patients with intermediate risk prostate cancer who receive hypofractionated EBRT?

There is no good evidence that with different radiotherapy dose/fx or other RT modalities that the relative benefit of ADT is any different. This applies also to SBRT, brachy, and combo-brachy.

The basic evidence and logic is as follows:

1. ADT improves MFS and OS in multiple RCTs using lower dose co...

I use the same criteria for the use of ADT for intermediate risk patients regardless of radiation duration (I.e. 2 Gy per fraction vs > 2 Gy per fraction). I offer ADT for unfavorable intermediate risk patients. I think that based on CHIIP there is no difference in ADT use based on dose per fraction...